Skip to main content
Caplight Logo









Serapha Bio

Serapha Bio

Private
United StatesHealthcare & Life Scienceshttps://www.seraphabio.com/

Last Round

Series A

Jun 23, 2026

Est. Valuation

$303.7M

Company Overview

Serapha Bio is a biotechnology company developing an investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

base editinggene editingin vivo therapyAlpha-1 Antitrypsin DeficiencyAATDgenetic disorderprecision medicinebiotechclinical-stage biotechtherapeutic assetgenetic medicinegenomic medicinedrug developmentCRISPR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Serapha Bio Comparables

Compare Serapha Bio with similar companies based on industry and business-model similarity.

Serapha Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AIRNA
89%
Beam Therapeutics
88%
Frequency Therapeutics
87%

Serapha Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 23, 2026

Serapha Bio Investors

Notable investors and investment history

Serapha Bio Filings

Explore SEC and related filing metadata, where available.

Serapha Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Serapha Bio's valuation, stock price, and market status.

Is Serapha Bio a public or private company?

Serapha Bio is a private company.

What is the current stock price of Serapha Bio?

Serapha Bio is a private company with no public stock price. Caplight tracks Serapha Bio's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Serapha Bio worth (valuation)?

Serapha Bio's valuation is estimated at $303.7M based on funding round data.

Can I buy Serapha Bio stock?

Serapha Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Serapha Bio's last funding round?

Serapha Bio's most recent funding round was Series A on June 23, 2026.

Who are the main investors in Serapha Bio?

Key investors in Serapha Bio include RA Capital Management, RTW Investments.

Will Serapha Bio IPO soon?

No public IPO plans have been announced for Serapha Bio.

How can I track Serapha Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Serapha Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersUnited States
Year Founded2026
Last FundingJun 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?